The Role of Synovitis in Osteoarthritis


Original post, click here
Primary Outcome Measures:

  • visual analog scale(VAS) [ Time Frame: before injection at baseline ]
  • visual analog scale(VAS) [ Time Frame: 4 weeks(first evaluation) ]
  • visual analog scale(VAS) [ Time Frame: 12 weeks(secondary evaluation) ]
  • The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index) [ Time Frame: before injection at baseline ]
  • The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index) [ Time Frame: 4 weeks(first evaluation) ]
  • The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index) [ Time Frame: 12 weeks(secondary evaluation) ]
Secondary Outcome Measures:

  • Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed simultaneously. [ Time Frame: before injection at baseline ]
  • Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed [ Time Frame: 4 weeks(first evaluation) ]
  • Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed [ Time Frame: 12 weeks(secondary evaluation) ]

Methods:

sixty patients with OA knee having unilateral or bilateral synovitis validated by ultrasound (N=40) were studied. All the patients were randomized to receive PRP (N=40) or Hyaluronic acid(HA)(N=40) injection twice at 2-week intervals; Clinical assessments were performed using a visual analog scale(VAS) and The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC index) before injection at baseline, 4 weeks(first evaluation) and 12 weeks(secondary evaluation). Imaging evaluation based on color Doppler ultrasound(CDUS) and the depth of synovial fluid accumulation ,and the width of synovial hypertrophy was performed simultaneously.